The team at VMBD will use the tool of metabolic engineering to transfer cannabis genetic pathways in microbes representing an alternative route to produce cannabinoids at an affordable and scalable manner.
The company said that the wide spread use of cannabis-based medicines for diseases including multiple sclerosis, chronic pain and many others needs large scale production of cannabinoids.
VMBD and its new approach will complement traditional greenhouse based production of plant material for rapid commercialization of active and derivative chemicals for both medical and recreational use.
In addition, microbial based cannabinoids are uniform and specific in composition which is critical in medicinal usage and overcomes diverse pharmacological activities otherwise related with different varieties or strains of plant materials.
VMBD CEO Syed Hussain Abidi said the microbial technology to produce key active cannabinoid molecules adds to the company’s growing platform technologies for mass production and extraction of marijuana oils.
"We believe the alternative microbial production route can reduce THC/CBD cost by ten times or more, adding to our competitive advantage in the industry," Abidi said.
"Our deep domain expertise in metabolic engineering and purification will allow rapid commercialization of cannabinoid based products in a fast growing market."
Verde Media Group is a publicly traded company listed on the OTC Markets trading under the stock symbol: VMGI.